MAB2

Live / Registered — Registered (as of 15 Aug 2023)

What this means for you

Registered since 15 Aug 2023. The owner can stop confusingly similar uses in the classes it covers.

Record

Serial number
90733679
Registration number
7135330
Mark type
Word mark
Filed
25 May 2021
Published for opposition
30 May 2023
Registered
15 Aug 2023
Attorney of record
Shoko Naruo

Goods and services

  • Class 001 — Chemicals: Biological preparations containing monoclonal antibodies for scientific, industrial, and research use; bispecific and multispecific monoclonal antibodies, and fragments thereof, for scientific, industrial, and research use
  • Class 005 — Pharmaceuticals: Pharmaceutical, biopharmaceutical and medical preparations, agents and substances, all containing or being monoclonal antibodies for medical purposes, and all for treatment of cancer, oncological diseases and disorders, infectious diseases and disorders, inflammation and diseases, disorders and conditions associated with inflammation, inflammatory diseases and disorders, and neurological diseases and disorders; bispecific and multispecific monoclonal antibodies for medical use; products in the nature of pharmaceutical preparations and medicines containing multispecific, in particular bispecific, monoclonal antibodies for use in medicine; diagnostic preparations, agents and substances, all containing or being monoclonal antibodies, for medical purposes
  • Class 042 — Scientific and technological services: Scientific and technological services, namely scientific research and design in the field of immunoglobulins and antibodies for medical purposes; scientific research, namely industrial analysis and research services, in the field of immunoglobulins and antibodies for medical purposes; pharmaceutical, scientific and biopharmaceutical research and development; medical research and development in the field of immunoglobulins and antibodies for medical purposes; drug discovery services; research relating to medicines; research and development of medicines; development of pharmaceutical and biopharmaceutical preparations and medicines; all of the foregoing involving monoclonal antibodies

Owner

Prosecution history

  • 30 Oct 2024 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
  • 15 Aug 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
  • 15 Aug 2023 — REGISTERED-PRINCIPAL REGISTER
  • 30 May 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 30 May 2023 — PUBLISHED FOR OPPOSITION
  • 10 May 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 27 Apr 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 27 Apr 2023 — EXAMINER'S AMENDMENT ENTERED
  • 27 Apr 2023 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
  • 27 Apr 2023 — EXAMINERS AMENDMENT E-MAILED
  • 27 Apr 2023 — EXAMINERS AMENDMENT -WRITTEN
  • 21 Mar 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
  • 20 Mar 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE
  • 20 Mar 2023 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
  • 20 Sept 2022 — NOTIFICATION OF NON-FINAL ACTION E-MAILED

View this trademark record on Marksy